Koyfin Home > Directory > Health Care > Acceleron Pharma > Gross Margin

Acceleron Pharma Gross Margin Chart (XLRN)

Acceleron Pharma annual/quarterly Gross Margin from 2012 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Acceleron Pharma Gross Margin for the quarter ending June 06, 2020 was $4m a 21,134.69% increase of 798m year over year
  • Acceleron Pharma Gross Margin for the last 12 months ending June 06, 2020 was $-85m a -194.42% increase of 166m year over year
  • Acceleron Pharma Annual Gross Margin for 2019 was $-108m a -494.68% increase of 535m from 2018
  • Acceleron Pharma Annual Gross Margin for 2018 was $-643m a 11.99% decrease of -77m from 2017
  • Acceleron Pharma Annual Gross Margin for 2017 was $-566m a 76.44% decrease of -432m from 2016
Other Margins & Efficiency Metrics:
  • Acceleron Pharma EBITDA Margin for the quarter ending March 03, 2016 was $-20m a -39.99% increase of 8m year over year
  • Acceleron Pharma Return on Capital % for the quarter ending September 09, 2018 was -23.05 a 14.16% decrease of -3.26 year over year
  • Acceleron Pharma Return on Equity % for the quarter ending September 09, 2018 was -35.54 a 13.15% decrease of -4.68 year over year
View Chart On Koyfin

Quarterly XLRN Gross Margin Data

06/2020$4m
03/2020$-767m
12/2019$-24m
09/2019$-794m
06/2019$-26m
03/2019$-1,079m
12/2018$-683m
09/2018$-657m
06/2018$-604m
03/2018$-625m

Annual XLRN Gross Margin Data

2019$-108m
2018$-643m
2017$-566m
2016$-133m
2015$-204m
2014$-225m
2013$37m
2012$-132m
2011$58m